Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
- Auteur
- OCKENHOUSE, C. F; SUN, P.-F; WIRTZ, R. A; SADOFF, J. C; KASLOW, D. C; KUMAR, S; CHURCH, L. W. P; CRUTCHER, J. M; WIZEL, B; HOFFMAN, S; LALVANI, A; HILL, A. V. S; LANAR, D. E; TINE, J. A; GUITO, K. P; DE TAISNE, C; ANDERS, R; HORII, T; PAOLETTI, E; BALLOU, W. R; WELLDE, B. T; HALL, B. T; KESTER, K; STOUTE, J. A; MAGILL, A; KRZYCH, U; FARLEY, L
Connaught Laboratories, Inc., Swiftwater, Pennsylvania, United States
Department of Immunology, Walter Reed Army Institute of Research, Washington, DC, United States
Institute of Molecular Medicine, University of Oxford, Headington, Oxford, United Kingdom
Laboratory of Parasitic, Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health and Malaria Program, Naval Medical Research Institute, Bethesda, Maryland, United States
Pasteur Mérieux Connaught, Marcy l'Etoile, France
Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Virogenetics Corp., Troy, New York, United States
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia - Source
The Journal of infectious diseases. 1998, Vol 177, Num 6, pp 1664-1673 ; ref : 27 ref
- CODEN
- JIDIAQ
- ISSN
- 0022-1899
- Domaine scientifique
- Immunology, immunopathology, allergology; Microbiology, infectious diseases; Tropical medicine
- Editeur
- University of Chicago Press, Chicago, IL
- Pays de publication
- United States
- Type de document
- Article
- Langue
- English
- Mot clé (fr)
- Efficacité Essai clinique phase II Evaluation performance Homme Immunogénicité Insertion Paludisme Plasmodium falciparum Toxicité Vaccination NYVAC-Pf7 Apicomplexa Infection Parasitose Protozoa Protozoose
- Mot clé (en)
- Efficiency Phase II trial Performance evaluation Human Immunogenicity Insertion Malaria Plasmodium falciparum Toxicity Vaccination Apicomplexa Infection Parasitosis Protozoa Protozoal disease
- Mot clé (es)
- Eficacia Ensayo clínico fase II Evaluación prestación Hombre Inmunogenicidad Inserción Paludismo Plasmodium falciparum Toxicidad Vacunación Apicomplexa Infección Parasitosis Protozoa Protozoosis
- Classification
- Pascal
- 002 Sciences biologiques et medicales / 002A Sciences biologiques fondamentales et appliquees. Psychologie / 002A11 Protozoaires / 002A11F Vaccins, immunsérums, immunoglobulines et anticorps monoclonaux thérapeutiques
- Discipline
- Protozoa Tropical medicine
- Provenance
- Inist-CNRS
- Base de données
- PASCAL
- Identifiant INIST
- 2343355
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Accès au Document
Installer sur votre navigateur
DOI
10.1086/515331 
https://dx.doi.org/10.1086/515331
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/515331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:3:\"177\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1664\";s:8:\"\u0000*\u0000epage\";s:4:\"1673\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"OCKENHOUSE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:26:{i:0;s:9:\"SUN, P.-F\";i:1;s:11:\"WIRTZ, R. A\";i:2;s:12:\"SADOFF, J. C\";i:3;s:12:\"KASLOW, D. C\";i:4;s:8:\"KUMAR, S\";i:5;s:15:\"CHURCH, L. W. P\";i:6;s:14:\"CRUTCHER, J. M\";i:7;s:8:\"WIZEL, B\";i:8;s:10:\"HOFFMAN, S\";i:9;s:10:\"LALVANI, A\";i:10;s:13:\"HILL, A. V. S\";i:11;s:11:\"LANAR, D. E\";i:12;s:10:\"TINE, J. A\";i:13;s:11:\"GUITO, K. P\";i:14;s:12:\"DE TAISNE, C\";i:15;s:9:\"ANDERS, R\";i:16;s:8:\"HORII, T\";i:17;s:11:\"PAOLETTI, E\";i:18;s:12:\"BALLOU, W. R\";i:19;s:12:\"WELLDE, B. T\";i:20;s:10:\"HALL, B. T\";i:21;s:9:\"KESTER, K\";i:22;s:12:\"STOUTE, J. A\";i:23;s:9:\"MAGILL, A\";i:24;s:9:\"KRZYCH, U\";i:25;s:9:\"FARLEY, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Panist
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/515331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:3:\"177\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1664\";s:8:\"\u0000*\u0000epage\";s:4:\"1673\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"OCKENHOUSE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:26:{i:0;s:9:\"SUN, P.-F\";i:1;s:11:\"WIRTZ, R. A\";i:2;s:12:\"SADOFF, J. C\";i:3;s:12:\"KASLOW, D. C\";i:4;s:8:\"KUMAR, S\";i:5;s:15:\"CHURCH, L. W. P\";i:6;s:14:\"CRUTCHER, J. M\";i:7;s:8:\"WIZEL, B\";i:8;s:10:\"HOFFMAN, S\";i:9;s:10:\"LALVANI, A\";i:10;s:13:\"HILL, A. V. S\";i:11;s:11:\"LANAR, D. E\";i:12;s:10:\"TINE, J. A\";i:13;s:11:\"GUITO, K. P\";i:14;s:12:\"DE TAISNE, C\";i:15;s:9:\"ANDERS, R\";i:16;s:8:\"HORII, T\";i:17;s:11:\"PAOLETTI, E\";i:18;s:12:\"BALLOU, W. R\";i:19;s:12:\"WELLDE, B. T\";i:20;s:10:\"HALL, B. T\";i:21;s:9:\"KESTER, K\";i:22;s:12:\"STOUTE, J. A\";i:23;s:9:\"MAGILL, A\";i:24;s:9:\"KRZYCH, U\";i:25;s:9:\"FARLEY, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Istex
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/515331\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Accès par Unpaywall
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/515331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:3:\"177\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1664\";s:8:\"\u0000*\u0000epage\";s:4:\"1673\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"OCKENHOUSE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:26:{i:0;s:9:\"SUN, P.-F\";i:1;s:11:\"WIRTZ, R. A\";i:2;s:12:\"SADOFF, J. C\";i:3;s:12:\"KASLOW, D. C\";i:4;s:8:\"KUMAR, S\";i:5;s:15:\"CHURCH, L. W. P\";i:6;s:14:\"CRUTCHER, J. M\";i:7;s:8:\"WIZEL, B\";i:8;s:10:\"HOFFMAN, S\";i:9;s:10:\"LALVANI, A\";i:10;s:13:\"HILL, A. V. S\";i:11;s:11:\"LANAR, D. E\";i:12;s:10:\"TINE, J. A\";i:13;s:11:\"GUITO, K. P\";i:14;s:12:\"DE TAISNE, C\";i:15;s:9:\"ANDERS, R\";i:16;s:8:\"HORII, T\";i:17;s:11:\"PAOLETTI, E\";i:18;s:12:\"BALLOU, W. R\";i:19;s:12:\"WELLDE, B. T\";i:20;s:10:\"HALL, B. T\";i:21;s:9:\"KESTER, K\";i:22;s:12:\"STOUTE, J. A\";i:23;s:9:\"MAGILL, A\";i:24;s:9:\"KRZYCH, U\";i:25;s:9:\"FARLEY, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Europe PubMed Central
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/515331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:3:\"177\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1664\";s:8:\"\u0000*\u0000epage\";s:4:\"1673\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"OCKENHOUSE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:26:{i:0;s:9:\"SUN, P.-F\";i:1;s:11:\"WIRTZ, R. A\";i:2;s:12:\"SADOFF, J. C\";i:3;s:12:\"KASLOW, D. C\";i:4;s:8:\"KUMAR, S\";i:5;s:15:\"CHURCH, L. W. P\";i:6;s:14:\"CRUTCHER, J. M\";i:7;s:8:\"WIZEL, B\";i:8;s:10:\"HOFFMAN, S\";i:9;s:10:\"LALVANI, A\";i:10;s:13:\"HILL, A. V. S\";i:11;s:11:\"LANAR, D. E\";i:12;s:10:\"TINE, J. A\";i:13;s:11:\"GUITO, K. P\";i:14;s:12:\"DE TAISNE, C\";i:15;s:9:\"ANDERS, R\";i:16;s:8:\"HORII, T\";i:17;s:11:\"PAOLETTI, E\";i:18;s:12:\"BALLOU, W. R\";i:19;s:12:\"WELLDE, B. T\";i:20;s:10:\"HALL, B. T\";i:21;s:9:\"KESTER, K\";i:22;s:12:\"STOUTE, J. A\";i:23;s:9:\"MAGILL, A\";i:24;s:9:\"KRZYCH, U\";i:25;s:9:\"FARLEY, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Base Search
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/515331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"1998\";s:9:\"\u0000*\u0000volume\";s:3:\"177\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1664\";s:8:\"\u0000*\u0000epage\";s:4:\"1673\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"OCKENHOUSE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:26:{i:0;s:9:\"SUN, P.-F\";i:1;s:11:\"WIRTZ, R. A\";i:2;s:12:\"SADOFF, J. C\";i:3;s:12:\"KASLOW, D. C\";i:4;s:8:\"KUMAR, S\";i:5;s:15:\"CHURCH, L. W. P\";i:6;s:14:\"CRUTCHER, J. M\";i:7;s:8:\"WIZEL, B\";i:8;s:10:\"HOFFMAN, S\";i:9;s:10:\"LALVANI, A\";i:10;s:13:\"HILL, A. V. S\";i:11;s:11:\"LANAR, D. E\";i:12;s:10:\"TINE, J. A\";i:13;s:11:\"GUITO, K. P\";i:14;s:12:\"DE TAISNE, C\";i:15;s:9:\"ANDERS, R\";i:16;s:8:\"HORII, T\";i:17;s:11:\"PAOLETTI, E\";i:18;s:12:\"BALLOU, W. R\";i:19;s:12:\"WELLDE, B. T\";i:20;s:10:\"HALL, B. T\";i:21;s:9:\"KESTER, K\";i:22;s:12:\"STOUTE, J. A\";i:23;s:9:\"MAGILL, A\";i:24;s:9:\"KRZYCH, U\";i:25;s:9:\"FARLEY, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:161:\"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par arXiv
